抗Ro52与抗Ro60双抗体阳性可识别最适合疾病修饰治疗临床试验的干燥综合征患者
该研究在839例疑似或确诊干燥综合征(SS)患者队列中,比较390例符合SS分类标准患者按抗Ro60和抗Ro52抗体状态分组的表型特征。双抗体阳性患者(占58%)异常眼表染色、灶性淋巴细胞性涎腺炎(灶评分≥1)、ANA≥1:320、抗SSB/La、类风湿因子和IgG≥15.6 g/L的患病率显著更高(P<0.0016)。结论提示双抗体阳性可作为靶向B细胞高活性和腺体炎症通路药物的临床试验入选标准。
要点
- 抗Ro60和抗Ro52双抗体阳性SS患者B细胞高活性和腺体炎症标志物患病率更高。
- 双抗体阳性可作为靶向相关致病通路的疾病修饰治疗临床试验的入选标准。
- 单独抗Ro52或抗Ro60阳性组间表型关联相似,仅类风湿因子在单抗Ro52组更高。
核心结论
- 抗Ro60和抗Ro52双抗体阳性SS患者以B细胞高活性和腺体炎症标志物高患病率为特征,可作为临床试验入选标准。
研究设计与样本
- 来自单中心多学科SS队列的839例连续疑似或确诊SS患者,其中390例符合SS分类标准。
主要发现
- 390例SS患者中,双抗体阳性227例(58%),单抗Ro60阳性65例(17%),单抗Ro52阳性58例(15%),双抗体阴性40例(10%)。
- 双抗体阳性组异常眼表染色、灶性淋巴细胞性涎腺炎伴灶评分≥1、ANA≥1:320、抗SSB/La、类风湿因子和IgG≥15.6 g/L的患病率显著更高(P<0.0016)。
- 单抗Ro52组与单抗Ro60组表型关联相似,仅类风湿因子在单抗Ro52组更高。
- 在母队列中,除唾液腺肿大和腮腺超声评分外,Ro抗体血清学谱的关联与SS队列相似。
关键数值与推荐
- 双抗体阳性组异常眼表染色、灶性淋巴细胞性涎腺炎伴灶评分≥1、ANA≥1:320、抗SSB/La、类风湿因子和IgG≥15.6 g/L的患病率显著更高(P<0.0016)。
临床怎么用
- 在SS临床试验中,可考虑将抗Ro60和抗Ro52双抗体阳性作为入选标准,以富集B细胞高活性和腺体炎症患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess anti-Ro52 and anti-Ro60 serologic profiles as markers of clinically relevant phenotypic subsets of patients with Sjögren's syndrome (SS). METHODS: From a cohort of 839 consecutive patients with suspected or established SS seen in our multidisciplinary SS center, we compared the association of key phenotypic features in 390 patients who fulfilled SS classification criteria and in the parent cohort, stratifed by the presence of both anti-Ro60 and anti-Ro52, anti-Ro60 alone, and anti-Ro52 alone. RESULTS: The SS cohort included 227 patients (58%) with both anti-Ro60 and anti-Ro52, 65 (17%) with anti-Ro60 alone, 58 (15%) with anti-Ro52 alone, and 40 (10%) with neither antibody. Those with both anti-Ro60 and anti-Ro52 had a significantly increased prevalence of abnormal ocular surface staining, focal lymphocytic sialadenitis with focus score ≥1, antinuclear antibody ≥1:320, anti-SSB/La, rheumatoid factor, and IgG ≥15.6 gm/liter (P < 0.0016 for all). The groups with isolated anti-Ro52 and anti-Ro60 were equivalent to each other in their phenotypic associations, except for rheumatoid factor, which was higher in the anti-Ro52 alone group. The associations of these Ro antibody serologic profiles were similar in the parent cohort, except for additional associations with salivary gland enlargement and parotid gland ultrasound score. CONCLUSION: SS patients with both anti-Ro60 and anti-Ro52 antibodies are distinguished by a higher prevalence of markers of B-cell hyperactivity and glandular inflammation. Antibody reactivity to both Ro60 and Ro52 may thus serve as an important inclusion criterion for SS patients in clinical trials where the therapeutic agent targets pathways mediating these pathogenic abnormalities.
引用
- Armağan B, Robinson SA, Bazoberry A, et al. Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies. Arthritis Care Res (Hoboken). 2022. PMID: 33742788. doi:10.1002/acr.24597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。